Mechanisms of hormone drug resistance
|
|
- Carol Wilkerson
- 5 years ago
- Views:
Transcription
1 Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, th May 2015.
2 Hormone receptor-positive breast cancer (HR+ BC): Most common presentation of breast cancer, 2/3 of breast cancers express ER and/or PR Premenop Postmenop Premenopauza Postmenopauza ER+/PR+ ER+/PR- ER-/PR+ ER-/PR- Elledge et al. Diseases of the Breast. 2 nd ed. 2000
3 Rationale for endocrine therapy in HR-positive BC Estrogen plays a critical role in the development and progression of HR+ breast cancers: ER signal transduction pathways are key promoter of tumor proliferation, survival and invasion Estrogen deprivation in breast tissue is basic rationale for endocrine therapy Endocrine therapy is an important class of target-directed therapy that blocks the growth-promoting effects of estrogen via ER
4 Anti-estrogen therapies in BC Timeline of approval for endocrine therapy agents Selective estrogen receptor modulators (SERMs), such as tamoxifen, which block activity of ER Third-generation aromatase inhibitors (AIs), estrogen synthesis inhibitors steroidal: anastrazole, letrozole nonsteroidal: exemestane Selective estrogen receptor down-regulators (SERDs), such as fulvestrant, which induce destabilisation/degradation of ER
5 Endocrine therapy in HR-positive disease Most patients with HR+ BC benefit from endocrine therapy: hormonal therapy improves clinical outcomes Endocrine therapy has become the mainstay of treatment in HRpositive early and particularly advanced disease Preserved endocrine responsiveness to first-line endocrine therapy allows successive use of several hormonal therapeutic options and thus prolongs time to introduction of chemotherapy Unfortunately, the majority of patients with HR+ advanced breast cancer will ultimately progress despite endocrine therapy: resistance is a major clinical problem de novo, intrinsic resistance acquired resistance New treatment options that restore endocrine sensitivity are needed!
6
7 ER-positive/HER2-negative ABC ET is the preferred option for HR+ disease, even in the presence of visceral disease, unless there is concern or proof of endocrine resistance or there is disease needing a fast response (LoE: 1 A) The preferred 1st line ET for postmenopausal patients is an aromatase inhibitor or tamoxifen, depending on type and duration of adjuvant ET (LoE: 1 A) Fulvestrant HD is also an alternative option (LoE: 1 B) AI + everolimus is also an option after progression on a non-steroidal AI (LoE: 1 B) Optimal post-ai treatment is uncertain. Available options include, but are not limited to, tamoxifen, another AI (with a different mechanism of action), fulvestrant HD, megestrol acetate and everolimus + AI (LoE: 1 A)
8 Endocrine resistance Primary endocrine resistance is defined as: relapse while on the first 2 years of adjuvant ET PD within first 6 ms of initiating 1 st line ET for mbc, while on ET Secondary (aquired) endocrine resistance is defined as: relapse while on adjuvant ET but after the first 2 years relapse within 12 months of completing adjuvant ET PD 6 months after initiating ET for mbc, while on ET (LoE: Expert opinion)
9 Mechanisms of endocrine resistance Upregulation of alternative signal transduction pathways ESR1 gene mutations Epihenetic modifications of the ESR1 gene Alterations in cell cycle signaling Mechanisms of endocrine resistance are a topic of active research in order to reverse resistance and improve the outcome of patients with HR+ breast tumors
10 Cross-talk between signal transduction pathways and ER signaling in endocrine-resistant breast cancer: Opportunities for targeted interventions Reprinted by permission from the American Association for Cancer Research: Johnston SR. Clin Cancer Res. 2005;11:889s-899s
11 Enhancing sensitivity to endocrine therapy: PI3K/AKT/mTOR inhibition in HR+ advanced BC mtor interacts with ER signaling as well as growth factors including IGF-1, VEGF, and ErbB1,2 RTKs: EGFR, HER2, IGF1-R ER ER PTEN Src CoA Inactivated suppressors PI3K E Aberrations of this pathway are common in multiple cancers, including BC3,4 P Ras TSC2 TSC1 Nonnuclear/ nongenomic AKT S6K1 Activation of transcription factors Proliferation Survival Invasion mtor Cellular metabolism Angiogenesis ER Nuclear/ genomic mtor inhibitor MAPK P P P P ER P ER P CoA EREs P CoA mtor is a central regulator of multiple signaling pathways involved in cancer P CoA AP-1 TFs AP-1/SP-1 TFs-REs Gene expression (GFs, RTKs) Furthermore, hyperactivation of the PI3K/AKT/mTOR pathway has been observed in endocrine-resistant BC cells4 Inhibition of the mtor pathway may enhance endocrine sensitivity by inhibiting ligand-independent activation of the estrogen receptor Dual blockade of the mtor and endocrine pathways via mtor inhibition in combination with endocrine therapy offers clinical benefits for patients progressing on NSAIs 1. Osborne CK, et al. Annu Rev Med. 2011;62: ; 2. Yamnik RL, et al. J Biol Chem. 2009;284(10): ; 3. Samuels Y, et al. Science. 2004;304(5670):554; 4. Miller TW, et al. J Clin Invest. 2010;120(7):
12 BOLERO-2: Everolimus + Exemestane in HR+ advanced breast cancer progressing during/after NSAI therapy N = 724 Postmenopausal ER+ Unresectable locally advanced or metastatic BC Recurrence or progression after letrozole or astrozole R 2:1 Breast cancer trials of OraL EveROlimus-2 Phase 3 trial EVE 10 mg daily + EXE 25 mg daily (n = 485) Placebo + EXE 25 mg daily (n = 239) Stratification 1. Sensitivity to prior hormonal therapy 2. Presence of visceral disease Endpoints Primary: PFS (local assessment) Secondary: OS, ORR, QOL, safety, bone markers, PK. Baselga J et al. N Engl J Med. 2012;366:
13 Probability of Event (%) BOLERO-2: Everolimus + Exemestane improves PFS in HR+ mbc Patients at Risk, n Everolimus Placebo HR: 0.36 (95% CI: ) log-rank P < Central Assessment Wks Everolimus + exemestane (median PFS: 10.6 mos) Placebo + exemestane (median PFS: 4.1 mos) PFS Local Assessment: 7.8 mos vs 3.2 mos, HR: 0.45 (95% CI: ) log-rank P <.0001 Baselga J et al. N Engl J Med 2012;366:
14 BOLERO-2: Final OS analysis (39-mo follow-up)
15 ER mutations in HR+ breast cancer Resistance in BC is characterized by loss of ER (Erα isoform) expression and ER gene mutations Current studies: Identify types of ER mutations with patient-derived xenograft models [1] Explored prevalence of ER mutations throughout natural history of ER+ breast cancer, emphasizing endocrine-resistant disease state [2] 1. Shao J et al. SABCS Abstract S Jeselsohn RM et al. SABCS Abstract S3-06
16 TP53 PIK3CA CCND1 MCL1 MYC FGFR1 ESR1 ERBB2 AKT1 NF1 PTEN Alteration Percentage Patients With LBD Mutations, % Effects of ER mutational status 40 Genomic Alterations in ER+ Tumors 50 Disease Progression and LBD Mutation Frequency Primary Metastasis P < Primary 12 Early Metastatic Disease Late Metastatic Disease Primary tumors very rarely have ER mutations, whereas ESR1 alterations were significantly more frequent in metastatic samples after endocrine treatment As the disease progresses from primary to early to late metastatic disease, the percentage of patients with LBD mutations increases LBD, ligand-binding domain Jeselsohn RM et al. SABCS Abstract S3-06
17 ER mutations in HR+ breast cancer Mutation of ESR1 found in tumors in patients with ER+ mbc Mutations led to resistance to endocrine therapy [1,2] Type of mutation leads to differential treatment resistance [1] Ligand-binding domain mutations: resistance to AIs; potentially treatable with high-dose fulvestrant or antiestrogens Gene translocations: resistance to classic endocrine treatment Gene amplifications: resistance to AIs; potentially treatable with estradiol or antiestrogens Mutations of ESR1 mostly absent in primary tumors, and correlate with increasing number of endocrine therapies [2] Mutations potential driver of endocrine resistance 1. Shao J et al. SABCS Abstract S Jeselsohn RM et al. SABCS Abstract S3-06
18 Breast cancer genome sequencing results Ellis MJ et al. Nature 2012;486:
19 Targeting cell cycle progression downstream of the activated ER: An efficient strategy for antagonizing constitutive ERα signaling? Rationale for CDK4/6 inhibitors in ER+ BC
20 PALOMA-1/TRIO-18 (Phase 2): Palbociclib (PD ) + LET vs LET, 1st-line ER+/HER2 ABC Finn RS et al. SABCS 2012; Abstract S1-6
21 PALOMA-1/TRIO-18: Interim PFS Aromatase Inhibitor + CDK4/6 Inhibitor improves PFS in ER+ mbc Finn RS et al. SABCS 2012; Abstract S1-6
22 PALOMA-1/TRIO-18: Final survival results Finn RS et al. AACR 2014; Abstract CT101
23 Ongoing phase 3 studies assessing CDK 4/6 inhibition
24 Epigenetics mechanisms regulating ER expression Epigenetics: refers to reversible changes in gene expression secondary to histone hypoacetylation and abnormal DNA methylation in the promoter region of important genes Epigenetic modifications: might be modulated with the use of agents such as histone deacetylase (HDAC) inhibitors or demethylating agents HDAC inhibitors are of great interest because of the frequency of detection of epigenetic alterations in ER-positive BC
25 ENCORE 301: Entinostat + EXE vs EXE 2nd-line ER+ ABC, Randomized Phase 2 ENtinostat Combinations Overcoming Resistance Entinostat: histone deacetylase (HDAC) inhibitor Yardley DA et al. J Clin Oncol 2013;31: ENCORE 301 trial: NCT
26 ENCORE 301: PFS and OS* *Overall survival was an exploratory endpoint Yardley DA et al. J Clin Oncol 2013;31:
27 Updates on systemic endocrine treatments for breast cancer Numerous clinical trials are ongoing to address the unmet therapeutic needs in postmenopausal patients with HR+ mbc progressing on existing therapies Studies investigating therapeutic strategies that combine sequential endocrine therapies with targeted agents such as PI3K/mTOR, CDK4/6 and HDAC inhibitors are particularly promising Further understanding of the signaling/crosstalk pathways should lead to identification of additional targets and development of more targeted agents that can combine with sequential endocrine therapy to overcome the mechanism of progression and improve outcomes
Multimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationLAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI)
LAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI) Prim Mr Sc Dr Suzana Vasović Institute for oncology and radiology of Serbia UMOS, X Conference, 16.05.2015 Belgrade How do we
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 9 th 2013 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationLa via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario
La via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario Alessandra Modena U.O.C. Oncologia Medica Direttore: Dott.ssa Stefania Gori Ospedale Sacro Cuore - Don Calabria 29 novembre 2016
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationEndocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 2012
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationHighlitghs in MBC First and second line endocrine treatments. Antonio Frassoldati Oncologia Clinica Ferrara
Highlitghs in MBC First and second line endocrine treatments Antonio Frassoldati Oncologia Clinica Ferrara Which clinical scenario have to face First line therapy with today? Untreated metastatic breast
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationAgents in the Treatment of ER+ Aromatase Inbitor-Resistant Metastatic Breast Cancer: M-THOR Inhibitors
Agents in the Treatment of ER+ Aromatase Inbitor-Resistant Metastatic Breast Cancer: M-THOR Inhibitors Valero, M.D., Professor of Medicine and Deputy Chairman Department of Breast Medical Oncology The
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationEndocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore
Endocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Outline Guidelines and Evolving Clinical Treatment Landscape for HR+ HER2-
More informationHormonal Management of Metastatic Breast Cancer
Hormonal Management of Metastatic Breast Cancer Dr. Khaled Abulkhair, PhD Medical Oncology SCE, Royal College, UK Ass. Professor of Clinical Oncology Mansoura University, Egypt Case For Discussion A 63
More informationPI3K/AKT/mTOR Inhibitors in Breast Cancer
PI3K/AKT/mTOR Inhibitors in Breast Cancer Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Global Breast Cancer Conference 2015 Outline Overview of PI3K/Akt/mTOR Pathway Rationale
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationBreast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
More informationBreast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease
Breast Cancer Carcinogenesis: Mechanisms and Pathways in Hormone Receptor Positive Disease 1 Nearly Two-Thirds of Metastatic Breast Cancers Express Hormone Receptors Breast cancer tumors are often classified
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationIntroduction. Ahmad Radzi 1*, Fabian Wei Luen Lee 2 REVIEW ARTICLE
doi: 10.18282/amor.v4.i1.255 REVIEW ARTICLE Optimizing treatment-sequencing strategies for the management of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: A
More informationASCO 2017 WEBCAST. Elacestrant (RAD1901) June, 4, 2017
ASCO 2017 WEBCAST Elacestrant (RAD1901) June, 4, 2017 NASDAQ: RDUS Disclaimer: RAD1901 is an investigational agent Please refer to the ASCO 2017 poster for complete details Safe Harbor Any statements made
More informationOptimizing therapy selection in ER[+] HER2[-] Advanced Breast Cancer
Optimizing therapy selection in ER[+] HER2[-] Advanced Breast Cancer Dr Antonio Llombart-Cussac, MD, PhD Medical Oncology Division Hospital Arnau Vilanova, Valencia, Spain Disclaimer The contents herein
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationCurrent Optimal Sequence and Duration of Endocrine Treatment
[Symposium 7] Present and Future of Endocrine Therapy 07 Apr, 2018@GBCC Current Optimal Sequence and Duration of Endocrine Treatment Breast Oncology Center The Cancer Institute Hospital of JFCR Shinji
More informationMetastatic HR+ Breast Cancer - CDK 4/6 Inhibitors Charting the Path. Sandy Sehdev MD FRCPC
Metastatic HR+ Breast Cancer - CDK 4/6 Inhibitors Charting the Path Sandy Sehdev MD FRCPC Objectives To understand the approach to the treatment of hormone sensitive metastatic breast cancer and the use
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationThe efficacy of second-line hormone therapy for recurrence during adjuvant hormone therapy for breast cancer
517734TAM6210.1177/1758834013517734Therapeutic Advances in Medical OncologyR Mori and Y Nagao research-article2013 Therapeutic Advances in Medical Oncology Original Research The efficacy of second-line
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Everolimus (Afinitor) for Advanced Breast Cancer March 25, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Everolimus (Afinitor) for Advanced Breast Cancer March 25, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationManagement of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers
Review Article Page 1 of 10 Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers Roger K. C. Ngan Department of Clinical Oncology, Queen Elizabeth
More informationTargeting mtor pathway in ER+/Her2- breast cancers. Fabrice ANDRE Gustave Roussy
Targeting mtor pathway in ER+/Her2- breast cancers Fabrice ANDRE Gustave Roussy Outline mtor pathway Clinical development of rapalogs in breast cancer Moving beyond rapalogs mtor pathway LKB1 Ras-raf-
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationAggiornamenti tra ricerca e clinica: il carcinoma della mammella
Aggiornamenti tra ricerca e clinica: il carcinoma della mammella Filippo Montemurro Unit of (INCO) Fondazione del Piemonte per l Oncologia Candiolo Cancer Institute (IRCCs) Research Needs in Breast Cancer
More informationUpdate on Systemic Treatment of Breast Cancer
Update on Systemic Treatment of Breast Cancer Christoph C. Zielinski Clinical Division of Oncology Department of Medicine I and Comprehensive Cancer Center (www.ccc.ac.at) Medical University Vienna - General
More informationEnhancing Endocrine Therapy for Hormone Receptor Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
JNCI J Natl Cancer Inst (2015) 107(10): djv212 doi:10.1093/jnci/djv212 First published online August 6, 2015 Review Enhancing Endocrine Therapy for Hormone Receptor Positive Advanced Breast Cancer: Cotargeting
More informationTranslational Platform for the Development of Targeted Therapeutics
Translational Platform for the Development of Targeted Therapeutics Ondřej Kalous, MD Associate Project Scientist UCLA Translational Oncology Research Laboratories (TORL) Jonsson Comprehensive Cancer Center
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationOnline-Only Supplementary Materials
Online-Only Supplementary Materials Online-Only Supplementary Methods: Eligibility Criteria and Study Endpoints and Assessments Supplementary Table 1. Demographic and Baseline Characteristics in Patients
More informationEnhancing Endocrine Therapy for Hormone Receptor Positive Advanced Breast Cancer
Enhancing Endocrine Therapy for Hormone Receptor Positive Advanced Breast Cancer Sung-Bae Kim, MD, PhD Professor, Dept of Oncology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationCDK4/6 inhibitors in advanced hormone receptor-positive breast cancer
Perspective CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer Romualdo Barroso-Sousa, Sara M. Tolaney Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Correspondence
More informationNSABP: FB-11. Shannon Puhalla, MD
NSABP: FB-11 Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib with Letrozole as Neoadjuvant Therapy in Post- Menopausal Women with Estrogen Receptor
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationOptimization of Hormone Treatment: New Alternative Sequences
Optimization of Hormone Treatment: New Alternative Sequences ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education
More informationUpdate mbc. endokrine Therapie
Update mbc endokrine Therapie HR neg ER pos Endokrine Resistenz Endokrine Therapie 1 st line Postmenopause AI/Tam/Fulvestrant 84% AI+ Fulvestrant 33% AI (Tam) + Everolimus 84% AI + CDK4/6 92% Prämenopause
More informationCancers du Sein Métastatiques
Cancers du Sein Métastatiques Véronique Diéras Journée Laurence Leroyer Rennes 18 mai 2018 Plan ESME Inhibiteurs CDK 4/6 RH+ Inhibiteurs PARP Anticorps drogue-conjugués Perspectives 2018-2019 ESME Time
More informationMetastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
More informationApproximately 70% of breast
Josh Lauring and Antonio C. Wolff Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer (J Clin Oncol 2016;34(25):2950 2952.)
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationMechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, mirnas and Genetically Based Resistance
Int. J. Mol. Sci. 2013, 14, 108-145; doi:10.3390/ijms14010108 Review OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Mechanisms of Resistance to Endocrine
More informationDEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc
DEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc Revue des essais cliniques en cours et perspectives Dr Cristian Villanueva CHRU Besançon
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationJohns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationClinical Oncology - Science in focus - Editorial. Understanding oestrogen receptor function in breast cancer, and its interaction with the
Clinical Oncology - Science in focus - Editorial TITLE: Understanding oestrogen receptor function in breast cancer, and its interaction with the progesterone receptor. New preclinical findings and their
More informationCase #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer
Case #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer Fellow Presenter: Katherine Clifton, MD Faculty Discussant: Debu Tripathy, MD 7 th Annual June 1, 2018 Topics to Be Discussed: Staging
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationPost-ESMO 2012: Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich T.Rordorf, SAMO Luzern 1
Post-ESMO 2012: Breast Cancer Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich 1 Neoadjuvant treatment (in Her-2 positive disease) neoadjuvant trials abstracts: breast sparing surgery, biomarkers,
More informationG1 Corporate Overview March 11, 2019
G1 Corporate Overview March 11, 2019 www.g1therapeutics.com NASDAQ: GTHX 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements within the
More informationCollaborative Management of Patients With Advanced Estrogen Receptor Positive Breast Cancer
Collaborative Management of Patients With Advanced Estrogen Receptor Positive Breast Cancer Lee Schwartzberg, MD, FACP Heather Greene, FNP, AOCNP West Cancer Center Memphis, Tennessee Learning Objectives
More informationClinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
ORIGINAL ARTICLE 2018 Mar 16. [Epub ahead of print] Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy Mi Hwa Heo, Hee Kyung Kim,
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationFunzionalità, Meccanismi di Escape, Potenziali Targets di Sinergismo Inibitorio. Federica Recine, MD
Studiando il Pathway di mtor Funzionalità, Meccanismi di Escape, Potenziali Targets di Sinergismo Inibitorio Federica Recine, MD Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome,
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationWhat do liquid biopsies offer us for breast cancer patients?
What do liquid biopsies offer us for breast cancer patients? Isaac Garcia-Murillas Breast Cancer Now Research Centre, The institute of Cancer Research, London, UK Molecular Analysis of breast cancer Invasive
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationInhibidores PI3K AKT -mtor Dr. Raquel Andrés HCU Lozano Blesa
Inhibidores PI3K AKT -mtor Dr. Raquel Andrés HCU Lozano Blesa PI3K/AKT/mTOR: Target For Treatment of HR+ Breast Cancer PI3K/mTOR is the most frequently activated signaling pathway in BC 1, leading to:
More information14,30 18,20. II Sessione. Moderatori: Giovanni Apolone, Roberto Labianca
14,30 18,20 II Sessione Moderatori: Giovanni Apolone, Roberto Labianca 14,30 14,50 Ca mammario: attualità e prospettive di ricerca Luca Livraghi Carcinoma mammario: attualità e prospettive di ricerca LUCA
More informationLo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento
Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento TRASTUZUMAB most important breakthrough in the management of BC Trastuzumab
More informationNovartis provided the study drug (everolimus) and research funding for this investigatorsponsored
1 TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients with hormone receptor positive, HER2-negative metastatic breast cancer with prior
More informationManagement of Hormone Receptor Positive Metastatic Breast Cancer
Management of Hormone Receptor Positive Metastatic Breast Cancer Adam Brufsky, MD, PhD Professor of Medicine University of Pittsburgh Improving Outcomes for Metastatic Breast Cancer Giordano SH 24 Chia
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationResistance to anti-her2 therapies. Service d Oncologie Médicale
Resistance to anti-her2 therapies Pr David Khayat Service d Oncologie Médicale Groupe Hospitalier Pitié Salpêtrière -Paris Disclosure statment Trastuzumab in HER2+ MBC A major impact but resistance will
More informationSABCS 2017 WEBCAST. Elacestrant (RAD1901) Update. December 7, 2017
SABCS 2017 WEBCAST Elacestrant (RAD1901) Update December 7, 2017 NASDAQ: RDUS Disclaimer: Elacestrant is an investigational agent Please refer to the SABCS 2017 poster for complete details Safe Harbor
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationC. Bourgier, I. Ray-Coquard, J. Provencal, C. Cropet, A.V. Bourcier, V. Delecroix, A. Reynaud-Bougnoux, J. Cretin, T. Bachelot
1 Exploratory Subgroup Analysis of the TAMRAD Phase 2 GINECO Trial Evaluating Tamoxifen (TAM) Plus Everolimus (RAD) vs TAM Alone in Patients With Hormone-Receptor Positive, HER2-Negative Metastatic Breast
More informationEndocrine therapy for ER-positive/HER2-negative metastatic breast cancer
Review Article Page 1 of 16 Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer Tomás Reinert 1,2, Bruno de Paula 3, Maryam Nemati Shafaee 4, Pedro Henrique Souza 5, Matthew J. Ellis
More informationFirst-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2 Breast Cancer
First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2 Breast Cancer Jack McCain In February 2015, the Food and Drug Administration (FDA) approved
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More information